Life Sciences Insight

CardieX Scores Blumio in New Acquisition

The deal comes after a successful three-year collaboration between the companies.

CardieX Limited, a global health technology company focused on cardiovascular disease, has acquired all the assets of Blumio, a Silicon Valley-based developer of advanced algorithms and technology for cardiovascular sensors. Blumio’s technology, according to CardieX, has the potential to significantly increase clinical performance for its catalog of heart health monitoring solutions.  

The acquisition comes after a positive three-year collaboration between the companies which demonstrated that Blumio’s sensor technology is compatible with ATCOR’s patented SphygmoCor arterial health technology — brands within CardieX. Bumio has led the charge in developing wearable sensor technologies that can capture a cardiovascular signal without necessitating the use of pulse pressure.

Bumio has led the charge in developing wearable sensor technologies that can capture a cardiovascular signal without necessitating the use of pulse pressure. It’s developed suite of data analytics and visualization tools are used to uncover insights in clinical data that contribute to CardieX’s current wearable development efforts. These tools “will enhance CardieX’s “Arty Heart Health Analytics Platform” to proactively monitor, alert, and provide actionable health insights from CardieX’s CONNEQT Pulse and CONNEQT Band devices – thereby enabling physicians and patients alike to make more informed healthcare decisions.”

“I’m very excited to join the CardieX group of companies,” said Catherine Liao, Blumio CEO. “We’ve come a long way with our development activities at Blumio and the time was right to bring that knowledge and technology into a company that shares our strong cultural alignment and focus on creating disruptive health solutions.”

Presently, financial terms of the transaction have not been disclosed.

“Blumio brings a suite of capabilities in wearable sensor development, signal processing, and big data analytics expertise that will benefit both of our ATCOR and CONNEQT brands, especially in relation to the ongoing development activities surrounding our CONNEQT Band,” said Craig Cooper, CardieX Group CEO. “This acquisition is a natural extension of our core solutions that provide a comprehensive ecosystem of unique health and wellness features focused on heart health.”

SHARE
Facebook
Twitter
LinkedIn